Cited by 549Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.

Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis

Open access

Navarese, Eliano P., Robinson, Jennifer G., Kowalewski, Mariusz, Kolodziejczak, Michalina, Andreotti, Felicita, Bliden, Kevin, Tantry, Udaya, Kubica, Jacek, Raggi, Paolo, Gurbel, Paul A.·2018·JAMA

DOI 10.1001/jama.2018.2525PMC PMC5933331

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Effects on specific fatal and nonfatal end points appear to vary for low-density lipoprotein cholesterol (LDL-C)-lowering drug trials. Objective: To evaluate whether baseline LDL-C level is associated with total and cardiovascular mortality risk reductions. Data Sourcesand Study Selection: Electronic databases (Cochrane, MEDLINE, EMBASE, TCTMD, ClinicalTrials.gov, major congress proceedings) were searched through February 2, 2018, to identify randomized clinical trials of statins, ezetimibe, and PCSK9-inhibiting monoclonal antibodies. Data Extraction and Synthesis: Two investigators abstracted data and appraised risks of bias. Intervention groups were categorized as "more intensive" (more potent pharmacologic intervention) or "less intensive" (less potent, placebo, or control group). Main Outcomes and Measures: The coprimary end points were total mortality and cardiovascular mortality. Random-effects meta-regression and meta-analyses evaluated associations between baseline LDL-C level and reductions in mortality end points and secondary end points including major adverse cardiac events (MACE). Results: In 34 trials, 136 299 patients received more intensive and 133 989 received less intensive LDL-C lowering. All-cause mortality was lower for more vs less intensive therapy (7.08% vs 7.70%; rate ratio [RR], 0.92 [95% CI, 0.88 to 0.96]), but varied by baseline LDL-C level. Meta-regression showed more intensive LDL-C lowering was associated with greater reductions in all-cause mortality with higher baseline LDL-C levels (change in RRs per 40-mg/dL increase in baseline LDL-C, 0.91 [95% CI, 0.86 to 0.96]; P = .001; absolute risk difference [ARD], -1.05 incident cases per 1000 person-years [95% CI, -1.59 to -0.51]), but only when baseline LDL-C levels were 100 mg/dL or greater (P < .001 for interaction) in a meta-analysis. Cardiovascular mortality was lower for more vs less intensive therapy (3.48% vs 4.07%; RR, 0.84 [95% CI, 0.79 to 0.89]) but varied by baseline LDL-C level. Meta-regression showed more intensive LDL-C lowering was associated with a greater reduction in cardiovascular mortality with higher baseline LDL-C levels (change in RRs per 40-mg/dL increase in baseline LDL-C, 0.86 [95% CI, 0.80 to 0.94]; P < .001; ARD, -1.0 incident cases per 1000 person-years [95% CI, -1.51 to -0.45]), but only when baseline LDL-C levels were 100 mg/dL or greater (P < .001 for interaction) in a meta-analysis. Trials with baseline LDL-C levels of 160 mg/dL or greater had the greatest reduction in all-cause mortality (RR, 0.72 [95% CI, 0.62 to 0.84]; P < .001; 4.3 fewer deaths per 1000 person-years) in a meta-analysis. More intensive LDL-C lowering was also associated with progressively greater risk reductions with higher baseline LDL-C level for myocardial infarction, revascularization, and MACE. Conclusions and Relevance: In these meta-analyses and meta-regressions, more intensive compared with less intensive LDL-C lowering was associated with a greater reduction in risk of total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels. This association was not present when baseline LDL-C level was less than 100 mg/dL, suggesting that the greatest benefit from LDL-C-lowering therapy may occur for patients with higher baseline LDL-C levels.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jama.2018.2525

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citation
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674

Flagged first, then by citations

Show all 58 references

2 of the 58 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

TiceJA; Institute for Clincal and Economic Review (ICER). Evolocumab for treatment of high cholesterol: clinical effectiveness: new evidence update. Institute for Clincal and Economic Review website. https://icer-review.org/material/pcks9-inhibitors-neu/. June 13, 2017. Accessed March 16, 2018.

Sorted by citations

Items 101–200 of 549

Association between low-density lipoprotein cholesterol and cardiovascular mortality in statin non-users: a prospective cohort study in 14.9 million Korean adults
Yi, S., An, S. J., Park, H., Yi, J., & Ohrr, H. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac029 · Cited by 28
StrokeClassifier: ischemic stroke etiology classification by ensemble consensus modeling using electronic health records
Lee, H., Schwamm, L. H., Sansing, L. H., Kamel, H., de Havenon, A., Turner, A. C., Sheth, K. N., Krishnaswamy, S., Brandt, C., Zhao, H., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01120-w · Cited by 29
Relationship between self-management behaviors and health-related quality of life among Chinese patients with coronary heart disease: A cross-sectional study
Zhang, Y., Yan, F., & Jiang, W. (2019) · Contemporary Nurse · doi:10.1080/10376178.2020.1731316 · Cited by 26
Effect of Ezetimibe Added to High-Intensity Statin Therapy on Low-Density Lipoprotein Cholesterol Levels: A Meta-Analysis
Lee, J., Egolum, U. O., Parihar, H. S., Cooley, M., & Ling, H. (2021) · Cardiology Research · doi:10.14740/cr1224 · Cited by 29
Low−/high-density lipoprotein cholesterol ratio and carotid plaques in patients with coronary heart disease: a Chinese cohort study
Li, Z., Cheng, Q., Liu, Y., Cheng, X., Wang, S., He, Y., Wang, X., Huang, M., Li, Y., Xue, X., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01575-w · Cited by 27
Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis
Li, X., Song, Y., Guo, T., Xiao, G., & Li, Q. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101366 · Cited by 30
Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization
Farkouh, M. E., Godoy, L. C., Brooks, M. M., Mancini, G. B. J., Vlachos, H. A., Bittner, V., CHAITMAN, B. R., Siami, F. S., Hartigan, P. M., Frye, R. L., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.536 · Cited by 27
Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis
Ma, W., Pan, Q., Pan, D., Xu, T., Zhu, H., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713007 · Cited by 26
Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes
Wharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02781-x · Cited by 26
Evidence of heterogeneity in statin-associated type 2 diabetes mellitus risk: A meta-analysis of randomized controlled trials and observational studies
Engeda, J. C., Stackhouse, A., White, M., Rosamond, W. D., Lhachimi, S. K., Lund, J. L., Keyserling, T. C., & Avery, C. L. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.04.005 · Cited by 29
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onset Diabetes: A Systematic Review and Meta-Analysis of Large, Double-Blinded Randomized Controlled Trials
Chiu, S., Pratt, C. M., Feinn, R., & Chatterjee, S. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420924983 · Cited by 26
Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis
Khan, S. U., Khan, M. U., Virani, S. S., Khan, M. S., Khan, M. Z., Rashid, M. O., Kalra, A., Alkhouli, M. A., Blaha, M. J., Blumenthal, R. S., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa093 · Cited by 29
Association of low-density lipoprotein cholesterol levels with the risk of mortality and cardiovascular events: A meta-analysis of cohort studies with 1,232,694 participants
Peng, K., Li, X., Wang, Z., Li, M., & Yang, Y. (2022) · Medicine · doi:10.1097/md.0000000000032003 · Cited by 25
Most Promising Therapies in Interventional Cardiology
Kernéis, M., Nafee, T., Yee, M. K., Kazmi, H. A., Datta, S., Zeitouni, M., Afzal, M. K., Jafarizade, M., Walia, S. S., Qamar, I., et al. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1108-x · Cited by 28
Dose-Response Associations of Lipid Traits With Coronary Artery Disease and Mortality
Yang, G., Mason, A. M., Wood, A., Schooling, C. M., & Burgess, S. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.52572 · Cited by 27
Increasing Medication Use and Polypharmacy in Type 2 Diabetes: The Danish Experience From 2000 to 2020
Johansson, K. S., Jimenez‐Solem, E., Petersen, T. S., & Christensen, M. (2024) · Diabetes Care · doi:10.2337/dc24-0011 · Cited by 24
Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients.
Li, Y., Chao, T.-H., Liu, P. Y., Ueng, K. C., & Yeh, H. I. (2018) · Europe PMC (PubMed Central) · doi:10.6515/acs.201809_34(5).20180629a · Cited by 24
Current pharmacotherapeutic options for primary dyslipidemia in adults
Cicero, A. F. G., Landolfo, M., Ventura, F., & Borghi, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1604687 · Cited by 24
Total cholesterol and mortality from ischemic heart disease and overall cardiovascular disease in Korean adults
Kwon, D., Yi, J., Ohrr, H., & Yi, S. (2019) · Medicine · doi:10.1097/md.0000000000017013 · Cited by 24
Metabolomics reveals the toxicological effects of polar compounds from frying palm oil
Yuan, L., Jiang, F., Cao, X., Liu, Y., & Xu, Y. (2020) · Food & Function · doi:10.1039/c9fo02728a · Cited by 24
Bibliometric and Visual Analysis on Metabolomics in Coronary Artery Disease Research
Yu, N., Wang, R., Liu, B., & Zhang, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.804463 · Cited by 24
F13A1 Gene Variant (V34L) and Residual Circulating FXIIIA Levels Predict Short- and Long-Term Mortality in Acute Myocardial Infarction after Coronary Angioplasty
ANSANI, L., Marchesini, J., Pestelli, G., Luisi, G. A., Scillitani, G., Longo, G., Milani, D., Serino, M. L., Tisato, V., & Gemmati, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092766 · Cited by 24
Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference
Butler, A. A., Price, C. A., Graham, J. L., Stanhope, K. L., King, S. M., Hung, Y.-H., Sethupathy, P., Wong, S. C., Hamilton, J., Krauss, R. M., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m089508 · Cited by 25
Association of acrylamide hemoglobin biomarkers with serum lipid levels in general US population: NHANES 2013–2016
Cheang, I., Liao, S., Zhu, X., Lu, X., Zhu, Q., Yao, W., Zhou, Y., Zhang, H., & Li, X. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112111 · Cited by 24
Dislipidemias y prevención del ictus: recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología
Palacio-Portilla, E. J., Roquer, J., Amaro, S., Arenillas, J. F., Martín, Ó. A., Castellanos, M., Freijo, M. D. M., Fuentes, B., Pastor, Á. G., Gomis, M., et al. (2020) · Neurología · doi:10.1016/j.nrl.2020.07.027 · Cited by 22
Meta‐Analysis of Intensive Lipid‐Lowering Therapy in Patients With Polyvascular Disease
Alkhalil, M., Kuzemczak, M., Whitehead, N., Kavvouras, C., & Džavík, V. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.017948 · Cited by 23
Time‐dependent lipid profile inversely associates with mortality in hemodialysis patients – independent of inflammation/malnutrition
Ebert, T., Qureshi, A. R., Lamina, C., Fotheringham, J., Froissart, M., Eckardt, K., Wheeler, D. C., Floege, J., Kronenberg, F., & Stenvinkel, P. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13291 · Cited by 23
Association of remnant cholesterol and non-high density lipoprotein cholesterol with risk of cardiovascular mortality among US general population
Cheang, I., Zhu, X., Lu, X., Shi, S., Tang, Y., Yue, X., Liao, S., Yao, W., Zhou, Y., Zhang, H., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10050 · Cited by 23
Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis
Ennezat, P. V., Guerbaaï, R.-A., Maréchaux, S., Jemtel, T. H. L., & François, P. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001345 · Cited by 24
Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
Khan, S. U., & Michos, E. D. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100013 · Cited by 23
Sea cucumber sulfated polysaccharides and Lactobacillus gasseri synergistically ameliorate the overweight induced by altered gut microbiota in mice
Liu, Z., Ai, C., Lin, X., Guo, X., Song, S., & Zhu, B. (2023) · Food & Function · doi:10.1039/d2fo03933h · Cited by 24
Advanced Applications of Nanomaterials in Atherosclerosis Diagnosis and Treatment: Challenges and Future Prospects
Tong, J., Wang, Z., Zhang, J., Gao, R., Liu, X., Liao, Y., Guo, X., & Wei, Y. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c13607 · Cited by 22
Evaluation of plasma sphingolipids as mediators of the relationship between kidney disease and cardiovascular events
Lidgard, B., Bansal, N., Zelnick, L. R., Hoofnagle, A. N., Fretts, A. M., Longstreth, W. T., Jr., Shlipak, M. G., Siscovick, D. S., Umans, J. G., & Lemaître, R. N. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104765 · Cited by 22
Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis
Khan, S. U., Riaz, H., Rahman, H., Khan, M. U., Khan, M. S., Alkhouli, M. A., Kaluski, E., Leucker, T. M., & Blaha, M. J. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.014 · Cited by 24
Preventable clinical and psychosocial factors predicted two out of three recurrent cardiovascular events in a coronary population
Sverre, E., Peersen, K., Weedon‐Fekjær, H., Perk, J., Gjertsen, E., Husebye, E., Gullestad, L. L., Dammen, T., Otterstad, J. E., & Munkhaugen, J. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01368-6 · Cited by 22
The Effects of Avocado Waste and Its Functional Compounds in Animal Models on Dyslipidemia Parameters
Pineda-Lozano, J. E., Moreno, A. G. M., & Carrillo, C. A. V. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.637183 · Cited by 21
Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review
Navarese, E. P., Andreotti, F., Raggi, P., Kołodziejczak, M. M., Buffon, A., Bliden, K. P., Tantry, U. S., Kubica, J., Sardella, G., Lauten, A., et al. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy038 · Cited by 22
Self-citation
Role of Statins in the Primary Prevention of Atherosclerotic Cardiovascular Disease and Mortality in the Population with Mean Cholesterol in the Near-Optimal to Borderline High Range: A Systematic Review and Meta-Analysis
Singh, B. M., Lamichhane, H. K., Srivatsa, S. S., Adhikari, P., Kshetri, B. J., Khatiwada, S., & Shrestha, D. B. (2020) · Advances in Preventive Medicine · doi:10.1155/2020/6617905 · Cited by 23
Predictive value of triglyceride/high-density lipoprotein cholesterol for major clinical outcomes in advanced chronic kidney disease: a nationwide population-based study
Kim, Y., Lee, S., Lee, Y., Kang, M. W., Park, S., Park, S. H., Han, K., Paek, J. H., Park, W. Y., Jin, K., et al. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa252 · Cited by 21
Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies
Bagepally, B. S., & Sasidharan, A. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03242-6 · Cited by 22
Role of angiopoietin-like protein 3 in sugar-induced dyslipidemia in rhesus macaques: suppression by fish oil or RNAi
Butler, A. A., Graham, J. L., Stanhope, K. L., Wong, S. C., King, S. M., Bremer, A. A., Krauss, R. M., Hamilton, J., & Havel, P. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000423 · Cited by 20
2022 Saudi Guidelines for the Management of Dyslipidemia
Alrahimi, J. S., AlSaif, S. M., Alasnag, M. A., Awan, Z. A., Almutairi, F., Mudaiheem, H. Y. A., Gencer, B., Catapano, A. L., Mach, F., & Tash, A. A. (2023) · Heart Views · doi:10.4103/heartviews.heartviews_102_22 · Cited by 21
Effects of Danhong injection on dyslipidemia and cholesterol metabolism in high-fat diets fed rats
Du, H., Li, C., Wang, Z., He, Y. T., Wang, Y., Zhou, H., Wan, H., & Yang, J. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114058 · Cited by 20
miR-1908 Dysregulation in Human Cancers
Shen, J., Wu, Y., Ruan, W., Zhu, F., & Duan, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.857743 · Cited by 20
Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study
Schleyer, T., Hui, S., Wang, J., Zhang, Z., Knapp, K., Baker, J., Chase, M., Boggs, R., & Simpson, R. J. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.5.544 · Cited by 19
Lipid levels achieved after a first myocardial infarction and the prediction of recurrent atherosclerotic cardiovascular disease
Ohm, J., Hjemdahl, P., Skoglund, P. H., Discacciati, A., Sundström, J., Hambræus, K., Jernberg, T., & Svensson, P. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.07.001 · Cited by 19
Ceramides improve cardiovascular risk prediction beyond low-density lipoprotein cholesterol
Leiherer, A., Muendlein, A., Saely, C. H., Laaksonen, R., Fraunberger, P., & Drexel, H. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oeae001 · Cited by 22
Discordance analyses comparing LDL cholesterol, Non-HDL cholesterol, and apolipoprotein B for cardiovascular risk estimation
Johannesen, C. D. L., Mortensen, M. B., Nordestgaard, B. G., & Langsted, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119139 · Cited by 22
Lipoprotein(a) and mortality—a high risk relationship
Klingel, R., Heibges, A., & Fassbender, C. (2019) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-019-00095-3 · Cited by 18
Association between cholesterol levels and dementia risk according to the presence of diabetes and statin use: a nationwide cohort study
Lee, Y., Kim, M. Y., Han, K., Kim, B., Park, J., Kim, G., Hur, K. Y., Kim, J. H., & Jin, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-24153-1 · Cited by 18
ApoB/ApoA-Ι is associated with major cardiovascular events and readmission risk of patients after percutaneous coronary intervention in one year
Zhang, J., Liu, M., Gao, J., Tian, X.-W., Song, Y., Zhang, H., & Zhao, P. (2025) · Scientific Reports · doi:10.1038/s41598-024-84092-x · Cited by 19
De-escalation of antiplatelets after percutaneous coronary intervention: a Bayesian network meta-analysis of various de-escalation strategies
Khan, S. U., Khan, M. Z., Khan, M. S., Mahmood, A., Kalra, A., Kaluski, E., Michos, E. D., & Alkhouli, M. A. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa025 · Cited by 18
Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects
Li, J., Liu, H.-H., Wu, N., Yeo, K. K., Tan, K. C. B., Ako, J., Krittayaphong, R., Tan, R., Aylward, P. E., Baek, S. H., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1802426 · Cited by 19
Meta-analysis of randomized clinical trials comparing PCSK9 monoclonal antibody versus ezetimibe/placebo in patients at high cardiovascular risk
Ma, W., Guo, X., Ma, Y., & Hu, Z. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.008 · Cited by 18
Effect of Perioperative Lipid Status on Clinical Outcomes after Cardiac Surgery
Mihalj, M., Heinisch, P. P., Huber, M., Schefold, J. C., Hartmann, A., Walter, M., Steinhagen‐Thiessen, E., Schmidli, J., Stüber, F., Räber, L., et al. (2021) · Cells · doi:10.3390/cells10102717 · Cited by 19
Maximizing the benefits of cholesterol-lowering drugs
Feingold, K. R. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000631 · Cited by 18
Safety and efficacy of antisense oligonucleotides on triglyceride, apolipoprotein C-III, and other lipid parameters levels in hypertriglyceridemia; a network meta-analysis of randomized controlled trials
Mahmoud, A., Abdelsayed, K., Mohamed, A. A., Najah, Q., Abdulkader, A., Ali, K., Tabassum, S., Abouzid, M. R., Abdelazeem, B., & Mills, J. D. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02389-2 · Cited by 17
Residual inflammatory risk after contemporary lipid lowering therapy
Riaz, H., Khan, S. U., Lateef, N., Talluri, S., Khan, M. S., & Desai, M. Y. (2019) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcz055 · Cited by 18
Remnant-Like Particle Cholesterol and the Risk of Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis
Yang, J., Wang, Y., Xi, Z., Ma, Y., Shao, C., Wang, W., & Tang, Y. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120452 · Cited by 18
Long-Lasting Control of LDL Cholesterol Induces a 40% Reduction in the Incidence of Cardiovascular Events: New Insights from a 7-Year Study
Trimarco, V., Izzo, R., Gallo, P., Manzi, M. V., Forzano, I., Pacella, D., Santulli, G., & Trimarco, B. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001878 · Cited by 18
Low LDL-C levels are associated with risk of mortality in a Chinese cohort study
Lu, J., Wu, M., Yang, Z., Zhu, Y., Li, D., Yu, Z., Shen, P., Tang, M., Jin, M., Lin, H., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02746-6 · Cited by 17
Serum Cholesterol and Impact of Age on Coronary Heart Disease Death in More Than 4 Million Veterans
Nguyen, X. T., Ho, Y.-L. A., Li, Y., Song, R. J., Leung, K. H., Rahman, S. U., Orkaby, A. R., Vassy, J. L., GAGNON, D. R., Cho, K., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030496 · Cited by 16
The Impact of Cardiometabolic Index on Cardiovascular Disease Risk Among Diabetic Patients: Evidence From Two National Cohorts
Liu, C., Zhang, Z., Meng, T., Wang, B., Li, C., Yu, X., & Zhang, X. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70044 · Cited by 16
New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease
Burger, A. L., Pogran, E., Muthspiel, M., Kaufmann, C. C., Jäger, B., & Huber, K. (2022) · Biomedicines · doi:10.3390/biomedicines10050970 · Cited by 17
Relationship between remnant cholesterol and risk of heart failure in participants with diabetes mellitus
Wang, R., Gerstein, H. C., Spall, H. G. C. V., Lip, G. Y. H., Olier, I., Ortega‐Martorell, S., Thabane, L., Ye, Z., & Li, G. (2023) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcad030 · Cited by 16
Lipid-Lowering Efficacy of Combination Therapy With Moderate-Intensity Statin and Ezetimibe Versus High-Intensity Statin Monotherapy: A Randomized, Open-Label, Non-Inferiority Trial From Korea
Choi, H., Kang, S., Jeong, S.-W., Yoon, C., Youn, T., Song, W. H., Jeon, D. W., Lim, S. W., Lee, J.-H., Cho, S.-W., et al. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.3.277 · Cited by 17
Statins plus ezetimibe in the era of proprotein convertase subtilisin/ kexin type 9 inhibitors
Luca, L. D., Corsini, A., Uguccioni, M., & Colivicchi, F. (2020) · Kardiologia Polska · doi:10.33963/kp.15529 · Cited by 17
Methods on LDL particle isolation, characterization, and component fractionation for the development of novel specific oxidized LDL status markers for atherosclerotic disease risk assessment
Papadea, P., Skipitari, M., Kalaitzopoulou, E., Varemmenou, A., Spiliopoulou, M., Papasotiriou, M., Papachristou, E. C., Goumenos, D. S., Onoufriou, A., Rosmaraki, E. E., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1078492 · Cited by 15
Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta‐Analysis
Zhang, X., Lan, R., Zhang, X., Xu, W., Wang, L., Kang, L., & Xu, B. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012428 · Cited by 15
Impact of diabetes on coronary severity and cardiovascular outcomes in patients with heterozygous familial hypercholesterolaemia
Liu, M., Peng, J., Guo, Y., Wu, N., Zhu, C., Gao, Y., Dong, Q., & Li, J. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab042 · Cited by 16
Efficacy of Statin/Ezetimibe for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Asian Populations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Bhagavathula, A. S., Aldhaleei, W. A., Matrooshi, N. O. A., & Rahmani, J. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00951-1 · Cited by 15
Association between baseline LDL-C and prognosis among patients with coronary artery disease and advanced kidney disease
Wang, B., Chen, S., Liu, J., Liang, Y., Meng, L., Yan, X., Huang, H., Chen, G., Huang, Z., Xu, D., et al. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02375-1 · Cited by 14
The impact of lipid-lowering medications on coronary artery plaque characteristics
Pulipati, V. P., & Alenghat, F. J. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100294 · Cited by 16
Approach to patients with elevated low-density lipoprotein cholesterol levels
Feingold, K. R., & Chait, A. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101658 · Cited by 18
Cholesterol affects the relationship between albumin and major adverse cardiac events in patients with coronary artery disease: a secondary analysis
Yao, Y., Chen, Z., Luo, T.-Y., Dou, X.-Y., & Chen, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-16963-0 · Cited by 15
Cholesterol-Lowering Strategies for Cardiovascular Disease Prevention: The Importance of Intensive Treatment and the Simplification of Medical Therapy
Sucato, V., Ortello, A., Comparato, F., Novo, G., & Galassi, A. R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071882 · Cited by 21
Lipid management beyond the guidelines
Robinson, J. G. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.10.004 · Cited by 15
Self-citation
Comparative efficacy and safety of statin and fibrate monotherapy: A systematic review and meta-analysis of head-to-head randomized controlled trials
Blais, J. E., Tong, G. K. Y., Pathadka, S., Mok, M. T. C., Wong, I. C. K., & Chan, E. W. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246480 · Cited by 15
Association of fine particulate matter with glucose and lipid metabolism: a longitudinal study in young adults
Qin, J., Xia, W., Liang, G., Xu, S., Zhao, X., Wang, D., Sun, X., Li, Y., & Liu, H. (2021) · Occupational and Environmental Medicine · doi:10.1136/oemed-2020-107039 · Cited by 15
Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy
Khan, S. U., Khan, M. U., Riaz, H., Raggi, P., Valavoor, S., Khan, M. Z., Kołodziejczak, M. M., Khan, M. S., Krupica, T., Alkhouli, M. A., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.12.006 · Cited by 14
Self-citation
Synthetic apolipoprotein A-I mimetic peptide 4F protects hearts and kidneys after myocardial infarction
Moreira, R. D. S., Irigoyen, M. C., Capcha, J. M. C., Sanches, T. R., Gutierrez, P. S., Garnica, M. R., Noronha, I. D. L., & Andrade, L. (2020) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00185.2019 · Cited by 14
l-Glutamine supplementation enhances glutathione peroxidase and paraoxonase-1 activities in HDL of exercising older individuals
Pires, R. S., Braga, P. G. S., Santos, J. M. B., do Amaral, J. B., Amirato, G. R., Trettel, C. D. S., Santos, C. A. F., Vaisberg, M. W., Nali, L. H. D. S., Vieira, R. P., et al. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111584 · Cited by 14
Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies
Sasidharan, A., Sajith Kumar, S., Jagadeesh, K. V., Natarajan, M., & Bagepally, B. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264563 · Cited by 14
Impact of Low Baseline Low‐Density Lipoprotein Cholesterol on Long‐Term Postdischarge Cardiovascular Outcomes in Patients With Acute Myocardial Infarction
Cho, K. H., Kim, M. C., Choo, E. H., Choi, I. J., Lee, S. N., Park, M., Park, C. S., Kim, H.-Y., Kim, C. J., Sim, D. S., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025958 · Cited by 14
The role of residual inflammatory risk and LDL cholesterol in patients with in-stent restenosis undergoing percutaneous coronary intervention
Zhang, H., Zhang, C., Zhang, Y., Tian, T., Wang, T., Chen, J., Qian, J., Hu, F., Dou, K., Qiao, S., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.05.009 · Cited by 14
Prevalence and Predictors of Out-of-Target LDL Cholesterol 1 to 3 Years After Myocardial Infarction. A Subanalysis From the EYESHOT Post-MI Registry
Silverio, A., Benvenga, R. M., Piscione, F., Gulizia, M. M., Meessen, J. M. T. A., Colivicchi, F., Nardi, F., Baldi, C., Galasso, G., Vecchione, C., et al. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420947633 · Cited by 14
Relation of Low-Density Lipoprotein Cholesterol Level to Plaque Rupture
Kurihara, O., Kim, H. O., Russo, M., Araki, M., Nakajima, A., Lee, H., Takano, M., Mizuno, K., & Jang, I. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.08.016 · Cited by 14
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease
Alkhalil, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180816141827 · Cited by 14
Effects of vitamin E administration on serum lipid profile in diabetic patients: a grade-assessed systematic review and dose–response meta-analysis of RCTs
Karimi, M., Karimi, M. A., Fayedeh, F., Kafi, F. Z., Kazemi, K., Jahangiri, S., & Asbaghi, O. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01833-2 · Cited by 16
Platelets as Potential Non-Traditional Cardiovascular Risk Factor—Analysis Performed in Healthy Donors
Szymańska, P., Luzak, B., Siarkiewicz, P., & Golański, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914914 · Cited by 13
Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies
Soroush, N., Shahraki, M. N., Jouabadi, S. M., Amiri, M., Aribas, E., Stricker, B. H. C., & Ahmadizar, F. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.04.015 · Cited by 16
Mendelian Randomization Studies in Atherosclerotic Cardiovascular Diseases
Ko, D. S., & Kim, Y. H. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.3.280 · Cited by 13
Long-term Management of Patients with Myocardial Infarction: An Updated Review
Chen, R., Zhao, H., & Yan, H. (2022) · Cardiology Discovery · doi:10.1097/cd9.0000000000000073 · Cited by 12
The relationship of low-density lipoprotein cholesterol and all-cause or cardiovascular mortality in patients with type 2 diabetes: a retrospective study
Chang, C.-H., Yeh, S., Ooi, S.-W., Li, C., & Chen, H.-F. (2023) · PeerJ · doi:10.7717/peerj.14609 · Cited by 12
Statin Treatment in Patients With Stroke With Low‐Density Lipoprotein Cholesterol Levels Below 70 mg/dL
Kim, J., Lee, K., Kim, B. J., Kang, J., Lee, K., Park, J., Kang, K., Lee, S. J., Kim, J. G., Cha, J., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030738 · Cited by 12
Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis
Jiang, Y., Wang, Y., Ma, S., Qian, L., Jing, Y., Chen, X., & Yang, J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1415668 · Cited by 16
Cardiovascular Disease in Patients With Systemic Lupus Erythematosus
Ballarano, C. A., & Frishman, W. H. (2021) · Cardiology in Review · doi:10.1097/crd.0000000000000383 · Cited by 12
IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study
Kubica, J., Podhajski, P., Magielski, P., Kubica, A., Adamski, P., Junik, R., Pinkas, J., & Navarese, E. P. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0148 · Cited by 12
Self-citation
Effect of PCSK9 Monoclonal Antibody Versus Placebo/Ezetimibe on Atrial Fibrillation in Patients at High Cardiovascular Risk: A Meta-Analysis of 26 Randomized Controlled Trials
Yang, S., Shen, W., Zhang, H., Wang, C., Yang, P., & Wu, Q. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07338-8 · Cited by 13
Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials
Gomes, D., Presume, J., Gonçalves, P. D. A., Almeida, M., Mendes, M., & Ferreira, J. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07547-3 · Cited by 15

Authors: Navarese, E. P., Robinson, J. G., Kowalewski, M., Kolodziejczak, M., Andreotti, F., Bliden, K., Tantry, U., Kubica, J., Raggi, P., & Gurbel, P. A.
Affiliations: Inova Health System (US)
University of Iowa (US)
Antoni Jurasz University Hospital (PL)
Systematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE Cardiovascular Research Network
Università Cattolica del Sacro Cuore (IT)
Nicolaus Copernicus University (PL)
University of Alberta (CA)
Corresponding author: Robinson, Jennifer G.
ORCID: Navarese, Eliano P.
Robinson, Jennifer G.
Kowalewski, Mariusz
Andreotti, Felicita
Tantry, Udaya
Kubica, Jacek
Raggi, Paolo
Gurbel, Paul A.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2018-04-17
Volume: 319
Issue: 15
Pages: 1566
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2018.2525
PMC: PMC5933331
OpenAlex: W2800876320
Semantic Scholar: e998030b0bef031f54619a07cde9f01df4ce9807
Cited by: 549
References: 58
Citations by year: 2026: 36 · 2025: 74 · 2024: 81 · 2023: 70 · 2022: 56 · 2021: 76 · 2020: 62 · 2019: 68 · 2018: 26
FWCI: 12.88
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: LDL cholesterol, LDL cholesterol lowering, statins, ezetimibe, PCSK9 inhibitors, all-cause mortality, cardiovascular mortality, major adverse cardiac events, lipid-lowering therapy, dose-response relationship, treatment intensity, risk stratification, randomized controlled trials, meta-regression, risk of bias assessment, risk difference, relative risk, number needed to harm
MeSH terms: Ezetimibe, Proprotein Convertase 9, PCSK9 Inhibitors, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Humans, Cholesterol, LDL, Mortality, Regression Analysis, Risk, Confounding Factors, Epidemiologic, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks